“In the third quarter we made significant progress toward delivering the benefits of nano-PFA to patients and providers around the world. Our clinical work with each of our three devices continues to suggest that our differentiated nano-PFA technology has the potential to improve treatments for several disease states by eradicating cells in a better way than currently available modalities,” said Burke T. Barrett, President and Chief Executive Officer of Pulse Biosciences (PLSE). “The work we have done to date positions us to begin pivotal clinical trials in the U.S. for each device next year and to also share select European trial data at medical conferences in the future. We are building our team and the infrastructure required to support our clinical and regulatory initiatives and anticipated growth, starting with commercial use of the nsPFA Percutaneous Electrode System in the coming quarters.”